icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial
 
 
  Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
 
Stefan Zeuzem,1Thomas Berg,2Edward Gane,3Peter Ferenci,4Graham R. Foster,5MichaelW.Fried,6Christophe Hezode,7Gideon Hirschfield,8Ira Jacobson,9 Igor Nikitin,10PaulPockros,11Fred Poordad,12Oliver Lenz,13Monika Peeters,13VanithaSekar,14GoedeleDeSmedt,13Maria Beumont-Mauviel13 1JW Goethe University Hospital, Frankfurt, Germany; 2University Clinic Leipzig, Leipzig, Germany; 3Auckland Hospital Clinical Studies Unit, Auckland, New Zealand; 4Universitätsklinik für Innere Medizin III, Wien, Austria; 5Queen Marys University of London, London, UK; 6University of North Carolina at Chapel Hill, NC, USA; 7Hôpital Henri-Mondor, Université Paris-Est Créteil, France; 8Toronto Western Hospital Liver Centre, Toronto, Canada; 9Weill Cornell Medical College, New York, NY, USA; 10Russian State Medical University, Moscow, Russia; 11Scripps Clinic, La Jolla, CA, USA; 12Cedars-Sinai Medical Center, Los Angeles, CA, USA; 13 Janssen Infectious Diseases BVBA, Beerse, Belgium; 14 Janssen Research & Development LLC, Titusville, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif